MGMT and glioblastoma: Whereas age commonly acts as an obstacle for the standard 6-week chemoradiation, the results of our study show that (i) standard CRT (> 80% completion rate) was feasible for ≥ 70 and even ≥ 80-year-old GBM patients; (ii) the survival rates (regardless of MGMT status) were rather comparable to the values for trial-selected and/or younger patients.